CRL · Earnings call · 2026Q2T · Full report

Strategic Initiatives

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 31 · Surprise 42

Charles River is investing in staffing, lab space, and laboratory expansions to support expected demand, including an expansion in Edinburgh near a university to assist with recruiting. Management said these expansions will not affect 2026 revenue but are intended to support growth in 2027 and beyond. The company is also modernizing laboratories through automation, digital systems, and laboratory equipment to improve speed, throughput, and utilization. Separately, management is developing a broad non-animal-methods strategy through internal development, in-licensing, partnerships, and client collaborations, integrating those technologies into Safety Assessment workflows rather than creating a standalone NAMs business.

Key facts

• The company will discuss long-term priorities and financial targets at an Investor Day on September 24.
• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. plans to develop NAMs via internal development, in-licensing, partnering and integration into Safety Assessment workflows rather than creating a standalone NAMs business.
• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. will host an Investor Day on September 24 and directs investors to ir.criver.com to register for the webcast.
• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. will provide a deeper presentation on modernization and NAMs development at its Investor Day.
• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. describes CRADL as focused on new companies and new biotech companies that have funding but do not want to create their own vivariums, providing space for early research and growth.